AVERTâ„¢ Clinical Trial
AVERTâ„¢ Clinical Trial
The Osprey Medical AVERT System is indicated to reduce contrast media (CM) exposure to the kidneys during percutaneous coronary procedures thereby reducing the risk of contrast induced nephropathy (CIN).
The purpose of this trial is to assess the AVERT System device, which is designed to limit the volume of CM (Contrast Media) utilized, during a staged therapeutic coronary PCI (Percutaneous Coronary Intervention) or a coronary diagnostic procedure that is anticipated to become a PCI (i.e. ad hoc PCI) for the reduction of CIN (Contrast Induced Nephropathy).
Inclusion Criteria:
Exclusion Criteria:
Jacksonville, Florida 32216, United States
Minneapolis, Minnesota 55407, United States